0.2222
price down icon3.60%   -0.0083
pre-market  Pre-market:  .22   -0.0022   -0.99%
loading
Carisma Therapeutics Inc stock is traded at $0.2222, with a volume of 646.86K. It is down -3.60% in the last 24 hours and down -44.59% over the past month.
See More
Previous Close:
$0.2305
Open:
$0.22
24h Volume:
646.86K
Relative Volume:
2.20
Market Cap:
$9.62M
Revenue:
$20.27M
Net Income/Loss:
$-63.80M
P/E Ratio:
-0.1462
EPS:
-1.52
Net Cash Flow:
$-68.35M
1W Performance:
-42.30%
1M Performance:
-44.59%
6M Performance:
-77.00%
1Y Performance:
-88.95%
1-Day Range:
Value
$0.2002
$0.23
1-Week Range:
Value
$0.2002
$0.4003
52-Week Range:
Value
$0.2002
$2.0497

Carisma Therapeutics Inc Stock (CARM) Company Profile

Name
Name
Carisma Therapeutics Inc
Name
Phone
(267) 491-6422
Name
Address
3675 MARKET STREET, PHILADELPHIA
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
CARM's Discussions on Twitter

Compare CARM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CARM
Carisma Therapeutics Inc
0.2222 9.62M 20.27M -63.80M -68.35M -1.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-12-24 Downgrade Robert W. Baird Outperform → Neutral
Dec-10-24 Downgrade BTIG Research Buy → Neutral
Apr-11-24 Initiated BTIG Research Buy
Oct-03-23 Initiated CapitalOne Overweight
Jul-06-23 Initiated Evercore ISI Outperform
May-31-23 Upgrade Jefferies Hold → Buy
May-24-23 Initiated H.C. Wainwright Buy
Apr-14-23 Initiated Robert W. Baird Outperform
View All

Carisma Therapeutics Inc Stock (CARM) Latest News

pulisher
Apr 02, 2025

Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - Inquirer.com

Apr 02, 2025
pulisher
Apr 02, 2025

Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo

Apr 02, 2025
pulisher
Apr 02, 2025

Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN

Apr 01, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Carisma Therapeutics Explores Sale Options as Company Halts R&D Programs - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st

Mar 28, 2025
pulisher
Mar 28, 2025

Carisma Therapeutics (CARM) to Release Earnings on Monday - Defense World

Mar 28, 2025
pulisher
Mar 22, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World

Mar 22, 2025
pulisher
Mar 13, 2025

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com

Mar 13, 2025
pulisher
Feb 25, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Feb 25, 2025
pulisher
Feb 22, 2025

Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN

Feb 22, 2025
pulisher
Feb 19, 2025

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow

Feb 19, 2025
pulisher
Feb 19, 2025

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow

Feb 19, 2025
pulisher
Feb 11, 2025

Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN

Feb 11, 2025
pulisher
Feb 05, 2025

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow

Feb 05, 2025
pulisher
Feb 04, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World

Feb 04, 2025
pulisher
Jan 31, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Jan 30, 2025
pulisher
Jan 24, 2025

Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees - BioSpace

Jan 24, 2025
pulisher
Jan 22, 2025

BTIG Downgrades Carisma Therapeutics (CARM) - MSN

Jan 22, 2025
pulisher
Jan 18, 2025

Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN

Jan 18, 2025
pulisher
Jan 18, 2025

Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 18, 2025
pulisher
Jan 14, 2025

Carisma Therapeutics (NASDAQ:CARM) Given “Buy” Rating at D. Boral Capital - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Lowers Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 14, 2025
pulisher
Jan 11, 2025

Carisma Therapeutics faces Nasdaq delisting over share price - Investing.com India

Jan 11, 2025
pulisher
Jan 10, 2025

Carisma Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada

Jan 10, 2025
pulisher
Jan 06, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts - Defense World

Jan 06, 2025
pulisher
Jan 03, 2025

Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World

Jan 03, 2025
pulisher
Dec 30, 2024

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 - GuruFocus.com

Dec 30, 2024
pulisher
Dec 27, 2024

4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology - Quantisnow

Dec 27, 2024
pulisher
Dec 26, 2024

Carisma Therapeutics Appoints Interim VP of Finance - TipRanks

Dec 26, 2024
pulisher
Dec 20, 2024

Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization - MSN

Dec 20, 2024
pulisher
Dec 18, 2024

Carisma downgraded by H.C. Wainwright to neutral - MSN

Dec 18, 2024
pulisher
Dec 17, 2024

Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright - Defense World

Dec 17, 2024
pulisher
Dec 16, 2024

HC Wainwright & Co. Downgrades Carisma Therapeutics (CARM) - MSN

Dec 16, 2024
pulisher
Dec 16, 2024

Carisma shares downgraded to neutral after program halt - Investing.com

Dec 16, 2024
pulisher
Dec 15, 2024

Carisma Therapeutics (NASDAQ:CARM) Cut to Neutral at Robert W. Baird - Defense World

Dec 15, 2024
pulisher
Dec 13, 2024

Carisma downgraded by Baird over lack of near-term catalysts - MSN

Dec 13, 2024
pulisher
Dec 13, 2024

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Kilgore News Herald

Dec 13, 2024
pulisher
Dec 12, 2024

Baird Downgrades Carisma Therapeutics (CARM) - MSN

Dec 12, 2024
pulisher
Dec 12, 2024

BTIG cuts Carisma Therapeutics to Neutral from Buy By Investing.com - Investing.com Nigeria

Dec 12, 2024

Carisma Therapeutics Inc Stock (CARM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):